Results 91 to 100 of about 80,637 (252)
Randomized, open-label, phase 2 study of nivolumab plus ipilimumab or nivolumab monotherapy in patients with advanced or metastatic solid tumors of high tumor mutational burden
Journal for ImmunoTherapy of CancerBackground Checkpoint inhibitor therapy has demonstrated overall survival benefit in multiple tumor types. Tumor mutational burden (TMB) is a predictive biomarker for response to immunotherapies.Alexandra Leary, Paolo A Ascierto, Michele Maio, Georgia Kollia, Jennifer Friedmann, Marina Tschaika, Patrick Schöffski, Jonathan Baden, Neeltje Steeghs, Parul Doshi, Massimo Di Nicola, Jean-Pierre Delord, Iwona Lugowska, Mauricio Burotto, David S P Tan, Anthony Gonçalves, Michael Schenker, Ning Huang, Tudor-Eliade Ciuleanu, Martin Richardet, Lorena Lupinacci, Julieta Grasselli, Jacqueline Vuky, Somasekhar Konduru, Sai Vikram Vemula, Ruta Slepetis, Misena Pacius, Quyen Duong +27 moredoaj +1 more sourceAbstract CT083: Clinical activity, immune and molecular correlates of nivolumab vs. nivolumab plus bevacizumab vs nivolumab plus ipilimumab in metastatic renal cell carcinoma
, 2017 Background: Immune checkpoint blockade including anti-CTLA-4 (ipilimumab, BMS) and anti-PD1 (nivolumab, BMS) as monotherapies have been known to have clinical activity against metastatic renal cell carcinoma (MRCC), but with relatively low clinical ...Luis M. Vence, Jose A. Karam, Tenghui Chen, Chaan S. Ng, Rebecca S. Slack, Jorge M. Blando, Nizar Tannir, Christopher G. Wood, Hao Zhao, Jianjun Gao, Eric Jonasch, Sreyashi Basu, Matthew Campell, Kamran Ahrar, Priya Rao, Padmanee Sharma, Surena Matin, Hong Chen, James P. Allison +18 morecore +1 more sourceTreatment‐Related Adverse Events and Health‐Related Quality of Life Associated With Immune Checkpoint Inhibitor Treatment for Mucosal Head and Neck Squamous Cell Carcinoma: A Scoping Review
Head &Neck, EarlyView.ABSTRACT Background
Supportive care needs of patients receiving immune checkpoint inhibitors (ICIs) for head and neck squamous cell carcinoma (HNSCC) are ill‐defined. Hence, known treatment‐related adverse events (TRAEs) and health‐related quality of life (HRQoL) associated with ICI treatment for HNSCC were examined to inform future supportive care ...N. D. O'Donnell, E. C. Ward, L. R. Wishart, R. Perera, C. Barrett, K. A. Edmiston, E. Mitchell, A. Pigott, R. Pitt, K. Russell, B. A. Chan, R. Ladwa +11 morewiley +1 more sourceSpotlight on nivolumab in the treatment of renal cell carcinoma: design, development, and place in therapy
, 2017 Vyshak Alva Venur,1 Monika Joshi,2 Kenneth G Nepple,3 Yousef Zakharia1 1Division of Hematology Oncology and Bone Marrow Transplant, Department of Internal Medicine, University of Iowa Hospitals and Clinics, Iowa City, IA, 2Division of Hematology ...Joshi M, Nepple KG, Zakharia Y, Venur VAcore Overall survival with combined nivolumab and ipilimumab in advanced melanoma [PDF]
, 2017 BACKGROUND: Nivolumab combined with ipilimumab resulted in longer progression-free survival and a higher objective response rate than ipilimumab alone in a phase 3 trial involving patients with advanced melanoma.Schadendorf D., Rutkowski, Piotr, Ivan Marquez-Rodas, Ascierto, P.A., Schadendorf D, Rutkowski P., Dummer R, Smylie, M., Wagstaff, J., Gonzalez R, Grob, J-J., Lao, C.D., Hogg, D., C. Lance Cowey, Haanen, J., Haanen, John, Marquez-Rodas I, Dummer R., McArthur G, Linda Rollin, Guidoboni M., Hill, Andrew, Ascierto PA, Sosman J., Dirk Schadendorf, Grob JJ, Larkin J, Jonathan Cebon, Carlino MS, Carlino, M.S., Celeste Lebbé, Grob, Jean-Jacques, Rollin L., Jedd D. Wolchok, Guidoboni M, Smylie M., Postow, M.A., Hill A., Hodi F. S., Maio M., Chiarion-Sileni, V., Margaret K. Callahan, Chiarion-Sileni V, Lebbe C, Jeffrey Sosman, Schadendorf, D., Piotr Rutkowski, Rollin L, Carlino M. S., Marquez-Rodas I., Bhore, R., Ferrucci, Pier F, Cowey CL, Gonzalez, Rene, Matteo S. Carlino, Callahan M. K., Vanna Chiarion-Sileni, Hogg, David, Ferrucci, P.F., Schadendorf, Dirk, Cebon J, Hodi FS, John Wagstaff, Bechter O., Pier F. Ferrucci, Dummer, R., Maio M, John Haanen, Callahan, M.K., Smylie M, Bhore R., Dana Walker, Hill, A., Smylie, Michael, Long G. V., Andrew Hill, Cebon, J., Walker D., Long, G.V., Wagstaff, John, Lebbe C., Lebbe, C., Hogg D, Gonzalez R., Bechter O, Cowey, C Lance, McArthur G., Larkin J., Massimo Guidoboni, Christopher D. Lao, Rutkowski, P., Michele Maio, Hill A, Maio, M., Ascierto P. A., Marquez-Rodas, I., David Hogg, Michael Smylie, Cowey, C.L., Wolchok, J.D., Wolchok J. D., Callahan MK, Cebon J., Wolchok JD, Sosman J, Dummer, Reinhard, Rene Gonzalez, Gonzalez, R., Jean-Jacques Grob, F. Stephen Hodi, Postow MA, Wagstaff J., Larkin, J., McArthur, G., Sosman, J., Bhore R, Grant McArthur, Haanen J, Bechter, Oliver, Wagstaff J, Paolo A. Ascierto, Carlino, Matteo S, Chiarion-Sileni V., Georgina V. Long, Postow M. A., Walker D, Cowey C. L., Chiarion-Sileni, Vanna, James Larkin, Reinhard Dummer, Oliver Bechter, Rutkowski P, Lao, Christopher D, Walker, D., Hogg D., Guidoboni, M., Ferrucci PF, Lao C. D., Grob J. -J., Ferrucci P. F., Haanen J., Hodi, F.S., Long GV, Rafia Bhore, Wolchok, Jedd D, et al, Rollin, L., Michael A. Postow, Lao CD +148 morecore +1 more sourceUnraveling the Plasma Extracellular Vesicles Proteome: Predictors of Resistance in Immunotherapy of Advanced Melanoma
International Journal of Cancer, EarlyView.ABSTRACT
Despite substantial clinical benefit from immune checkpoint inhibitors (ICI), advanced melanoma remains challenging due to frequent treatment resistance. Resistance may be intrinsic (primary) or emerge over time (secondary). Biomarkers predicting distinct resistance phenotypes before therapy are lacking.Julian Kött, Glenn Geidel, Carmen M. T. Roeper, Lucija Ačkar, Bente Siebels, Hannah Voß, Hartmut Schlüter, Michaela Schweizer, Kilian Müller, Alessandra Rünger, Tim Zell, Benjamin Deitert, Ali Zeinal‐Abedini, Isabel Heidrich, Stefan W. Schneider, Klaus Pantel, Daniel J. Smit, Christoffer Gebhardt +17 morewiley +1 more sourcePartial response of pulmonary adenocarcinoma with symptomatic brain metastasis to nivolumab plus high-dose oral corticosteroid: a case report
Journal of Medical Case Reports, 2017 Background Nivolumab, a monoclonal antibody targeting the programmed death-1 receptor, is indicated in locally advanced or metastatic non-small cell lung cancer, with progression after platinum-based chemotherapy.Hélène Pluchart, Julian Pinsolle, Julien Cohen, Gilbert R. Ferretti, Pierrick Bedouch, Matteo Giaj Levra, Anne-Claire Toffart, Denis Moro-Sibilot +7 moredoaj +1 more sourceTolerability of Adjuvant Nivolumab in Esophageal or Gastroesophageal Junction Cancer: A Real‐World Study
International Journal of Cancer, EarlyView.ABSTRACT
Adjuvant nivolumab is approved for esophageal or gastroesophageal junction cancer after neoadjuvant chemoradiotherapy and resection. In the CheckMate‐577 trial, Grade 3–5 nivolumab‐related adverse events (AEs) occurred in 5% of patients, with early discontinuation due to toxicity in 9%. However, real‐world data on immunotherapy‐related adverse Michelle Koops van ’t Jagt, Anniek Strijdhorst, Tamara Jessica Huizer, Esther Albertien Kleibeuker, Sarah Derks, Bianca Mostert, Hanneke van Laarhoven, Jacco Juri de Haan +7 morewiley +1 more sourceNivolumab induced myxedema crisis
Journal for ImmunoTherapy of Cancer, 2017 Background Nivolumab is an anti-programmed cell death (anti-PD-1) monoclonal antibody that is approved by Food and Drug Administration for treatment of metastatic non-small cell lung cancer, metastatic melanoma, relapsed Hodgkin lymphoma and advanced ...Uqba Khan, Humaira Rizvi, Dahlia Sano, Jane Chiu, Tarik Hadid +4 moredoaj +1 more source
